PMID- 32604721
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 26
TI  - Effects of 3-Month Astaxanthin Supplementation on Cardiac Function in Heart 
      Failure Patients with Left Ventricular Systolic Dysfunction-A Pilot Study.
LID - 10.3390/nu12061896 [doi]
LID - 1896
AB  - Astaxanthin has strong antioxidant properties. We conducted a prospective pilot 
      study on heart failure (HF) patients with left ventricular (LV) systolic 
      dysfunction to investigate improvements in cardiac function and exercise 
      tolerance in relation to suppression of oxidative stress by 3-month astaxanthin 
      supplementation. Oxidative stress markers-serum Diacron reactive oxygen 
      metabolite (dROM), biological antioxidant potential (BAP), and urinary 
      8-hydroxy-2'-deoxyguanosine (8-OHdG) concentrations, LV ejection fraction (LVEF), 
      and 6-min walk distance (6MWD) were assessed before and after 3-month astaxanthin 
      supplementation. Finally, the data of 16 HF patients were analyzed. Following 
      3-month astaxanthin supplementation, dROM level decreased from 385.6 +/- 82.6 
      U.CARR to 346.5 +/- 56.9 U.CARR (p = 0.041) despite no changes in BAP and urinary 
      8-OHdG levels. LVEF increased from 34.1 +/- 8.6% to 38.0 +/- 10.0% (p = 0.031) and 
      6MWD increased from 393.4 +/- 95.9 m to 432.8 +/- 93.3 m (p = 0.023). Significant 
      relationships were observed between percent changes in dROM level and those in 
      LVEF. In this study, following 3-month astaxanthin supplementation, suppressed 
      oxidative stress and improved cardiac contractility and exercise tolerance were 
      observed in HF patients with LV systolic dysfunction. Correlation between 
      suppression of oxidative stress and improvement of cardiac contractility suggests 
      that suppression of oxidative stress by astaxanthin supplementation had 
      therapeutic potential to improve cardiac functioning.
FAU - Kato, Takao
AU  - Kato T
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Kasai, Takatoshi
AU  - Kasai T
AUID- ORCID: 0000-0001-5747-7668
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital, Tokyo 
      113-8421, Japan.
FAU - Sato, Akihiro
AU  - Sato A
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Ishiwata, Sayaki
AU  - Ishiwata S
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Yatsu, Shoichiro
AU  - Yatsu S
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Matsumoto, Hiroki
AU  - Matsumoto H
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Shitara, Jun
AU  - Shitara J
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Murata, Azusa
AU  - Murata A
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Shimizu, Megumi
AU  - Shimizu M
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Suda, Shoko
AU  - Suda S
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital, Tokyo 
      113-8421, Japan.
FAU - Hiki, Masaru
AU  - Hiki M
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
FAU - Naito, Ryo
AU  - Naito R
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
AD  - Sleep and Sleep-Disordered Breathing Center, Juntendo University Hospital, Tokyo 
      113-8421, Japan.
FAU - Daida, Hiroyuki
AU  - Daida H
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo 113-8421, Japan.
LA  - eng
GR  - 26507010/Grant-in-Aid for Scienti fi c Research/
GR  - JP17K09527/JSPS KAKENHI/
GR  - H29-027/The Intractable Respiratory Diseases and Pulmonary Hypertension Research 
      Group from the Ministry of Health, Labor and Welfare/
GR  - 11/MEXT *-Supported Program for the Strategic Research Foundation at Private 
      Universities, 2014-2018 ( *Ministry of Education, Culture, Sports, Science and 
      Technology)/
GR  - 11/AstaReal Co., Ltd/
PT  - Journal Article
DEP - 20200626
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Antioxidants)
RN  - 0 (Xanthophylls)
RN  - 8XPW32PR7I (astaxanthine)
SB  - IM
MH  - Aged
MH  - Antioxidants/administration & dosage
MH  - Dietary Supplements
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/drug effects/physiology
MH  - Oxidative Stress/drug effects/physiology
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Stroke Volume/drug effects
MH  - Ventricular Dysfunction, Left/*drug therapy/physiopathology
MH  - Ventricular Function, Left/drug effects
MH  - Xanthophylls/administration & dosage
PMC - PMC7353230
OTO - NOTNLM
OT  - 6-min walk test
OT  - antioxidant
OT  - left ventricular ejection fraction
OT  - oxidative stress
COIS- Sato, Ishiwata, Naito, and Kasai are affiliated with a department endowed by 
      Philips, Fukuda Denshi, and ResMed. Daida received manuscript fees, research 
      funds, and scholarship funds from Kirin Co. Ltd., Kaken Pharmaceutical Co. Ltd., 
      Abbott Japan Co. Ltd., Astellas Pharma Inc., Astrazeneca K.K., Bayer Yakuhin 
      Ltd., Boston Scientific Japan K.K., Bristol-Myers Squibb, Daiichi Sankyo Company, 
      MSD K.K., Pfizer Inc., Philips, Sanofi K.K., and Takeda Pharmaceutical Co. Ltd. 
      Other authors report no conflicts of interest.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/20 06:00
PMCR- 2020/06/01
CRDT- 2020/07/02 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - nu12061896 [pii]
AID - nutrients-12-01896 [pii]
AID - 10.3390/nu12061896 [doi]
PST - epublish
SO  - Nutrients. 2020 Jun 26;12(6):1896. doi: 10.3390/nu12061896.